J&J axes pair of CAR-T therapies for lymphoma, citing evolving market
Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease. The drugmaker
May 1, 2026 07:07 AM EDT R&DCell/Gene Tx J&J axes pair of CAR-T therapies for lymphoma, citing evolving market Ayisha Sharma News Reporter Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that